0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ultrasensitive and Rapid Detection of Procalcitonin via Waveguide-Enhanced Nanogold-Linked Immunosorbent Assay for Early Sepsis Diagnosis

      rapid-communication

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sepsis, a life-threatening inflammatory response, demands economical, accurate, and rapid detection of biomarkers during the critical “golden hour” to reduce the patient mortality rate. Here, we demonstrate a cost-effective waveguide-enhanced nanogold-linked immunosorbent assay (WENLISA) based on nanoplasmonic waveguide biosensors for the rapid and sensitive detection of procalcitonin (PCT), a sepsis-related inflammatory biomarker. To enhance the limit of detection (LOD), we employed sandwich assays using immobilized capture antibodies and detection antibodies conjugated to gold nanoparticles to bind the target analyte, leading to a significant evanescent wave redistribution and strong nanoplasmonic absorption near the waveguide surface. Experimentally, we detected PCT for a wide linear response range of 0.1 pg/mL to 1 ng/mL with a record-low LOD of 48.7 fg/mL (3.74 fM) in 8 min. Furthermore, WENLISA has successfully identified PCT levels in the blood plasma of patients with sepsis and healthy individuals, offering a promising technology for early sepsis diagnosis.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Sepsis biomarkers: a review

          Introduction Biomarkers can be useful for identifying or ruling out sepsis, identifying patients who may benefit from specific therapies or assessing the response to therapy. Methods We used an electronic search of the PubMed database using the key words "sepsis" and "biomarker" to identify clinical and experimental studies which evaluated a biomarker in sepsis. Results The search retrieved 3370 references covering 178 different biomarkers. Conclusions Many biomarkers have been evaluated for use in sepsis. Most of the biomarkers had been tested clinically, primarily as prognostic markers in sepsis; relatively few have been used for diagnosis. None has sufficient specificity or sensitivity to be routinely employed in clinical practice. PCT and CRP have been most widely used, but even these have limited ability to distinguish sepsis from other inflammatory conditions or to predict outcome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Biomarkers of sepsis

            Sepsis is an unusual systemic reaction to what is sometimes an otherwise ordinary infection, and it probably represents a pattern of response by the immune system to injury. A hyper-inflammatory response is followed by an immunosuppressive phase during which multiple organ dysfunction is present and the patient is susceptible to nosocomial infection. Biomarkers to diagnose sepsis may allow early intervention which, although primarily supportive, can reduce the risk of death. Although lactate is currently the most commonly used biomarker to identify sepsis, other biomarkers may help to enhance lactate’s effectiveness; these include markers of the hyper-inflammatory phase of sepsis, such as pro-inflammatory cytokines and chemokines; proteins such as C-reactive protein and procalcitonin which are synthesized in response to infection and inflammation; and markers of neutrophil and monocyte activation. Recently, markers of the immunosuppressive phase of sepsis, such as anti-inflammatory cytokines, and alterations of the cell surface markers of monocytes and lymphocytes have been examined. Combinations of pro- and anti-inflammatory biomarkers in a multi-marker panel may help identify patients who are developing severe sepsis before organ dysfunction has advanced too far. Combined with innovative approaches to treatment that target the immunosuppressive phase, these biomarkers may help to reduce the mortality rate associated with severe sepsis which, despite advances in supportive measures, remains high.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Update on Procalcitonin Measurements

              Procalcitonin (PCT) is used as a biomarker for the diagnosis of sepsis, severe sepsis and septic shock. At the same time, PCT has also been used to guide antibiotic therapy. This review outlines the main indications for PCT measurement and points out possible pitfalls. The classic indications for PCT measurement are: (i) confirmation or exclusion of diagnosis of sepsis, severe sepsis, or septic shock, (ii) severity assessment and follow up of systemic inflammation mainly induced by microbial infection, and (iii) individual, patient adapted guide of antibiotic therapy and focus treatment. Using serially monitored PCT levels, the duration and need of antibiotic therapy can be better adapted to the individual requirements of the patient. This individualized approach has been evaluated in various studies, and it is recommended to be a part of an antibiotic stewardship program.
                Bookmark

                Author and article information

                Journal
                Nano Lett
                Nano Lett
                nl
                nalefd
                Nano Letters
                American Chemical Society
                1530-6984
                1530-6992
                22 January 2024
                28 February 2024
                : 24
                : 8
                : 2596-2602
                Affiliations
                []Department of Mechanical Engineering, National Chung Cheng University , Chiayi 621301, Taiwan
                []Advanced Institute of Manufacturing with High-Tech Innovations (AIM-HI), National Chung Cheng University , Chiayi 621301, Taiwan
                [§ ]Department of Chemistry and Biochemistry, National Chung Cheng University , Chiayi 621301, Taiwan
                []Department of Laboratory Medicine, National Taiwan University Hospital Yunlin Branch , Yunlin 640, Taiwan
                []Department of Critical Care Medicine, Taichung Veterans General Hospital , Taichung 402202, Taiwan
                [f ]Center for Nano Bio-Detection, National Chung Cheng University , Chiayi 621301, Taiwan
                Author notes
                [* ]L.-K.C.: email, chelkc@ 123456ccu.edu.tw .
                [* ]G.-E.C.: email, imegec@ 123456ccu.edu.tw .
                Author information
                https://orcid.org/0009-0000-1719-9317
                https://orcid.org/0000-0002-1659-6465
                https://orcid.org/0000-0002-3739-5451
                Article
                10.1021/acs.nanolett.3c04762
                10906069
                38251930
                49d583c1-1b96-4d46-8727-c668d278bfa6
                © 2024 The Authors. Published by American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 07 December 2023
                : 18 January 2024
                : 16 January 2024
                Funding
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: MOST 108-2119-M-194-002
                Funded by: National Taiwan University Hospital Yunlin Branch, doi 10.13039/501100022294;
                Award ID: NTUHYL 112-C008
                Funded by: National Taiwan University Hospital Yunlin Branch, doi 10.13039/501100022294;
                Award ID: NTUHYL 112-AI006
                Funded by: National Taiwan University Hospital Yunlin Branch, doi 10.13039/501100022294;
                Award ID: NTUHYL 111.C029
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: NSTC 112-2124-M-194-001
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: NSTC 111-2124-M-194-002
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: MOST 110-2636-E-194-002
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: MOST 110-2123-M-194-001
                Funded by: National Science and Technology Council, doi 10.13039/501100020950;
                Award ID: MOST 109-2123-M-194-001
                Categories
                Letter
                Custom metadata
                nl3c04762
                nl3c04762

                Nanotechnology
                planar waveguide,particle plasmon resonance,optical biosensor,point of care,procalcitonin,sepsis

                Comments

                Comment on this article